[{"orgOrder":0,"company":"Wize Pharma","sponsor":"Bonus BioGroup","pharmaFlowCategory":"D","amount":"$7.4 million","upfrontCash":"Undisclosed","newsHeadline":"Wize Pharma Executes Agreements for Strategic Transaction with Bonus BioGroup","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase IV","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Wize Pharma"},{"orgOrder":0,"company":"Wize Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wize Pharma Completes Phase IV Study of LO2A for the Treatment of Dry Eye Syndrome in Patients with Sj\u00f6gren's Syndrome","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase IV","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"May 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Wize Pharma"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recent 24-Month Real-World PALADIN Data Demonstrate the Ability of ILUVIEN\u00ae to Significantly Reduce Treatment Burden in Patients with Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Alimera Sciences"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 4 PALADIN Study with ILUVIEN\u00c2\u00ae Published in Peer-Reviewed Journal Ophthalmology","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Alimera Sciences"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 4 PALADIN Study Confirms Positive Predictive Value of Corticosteroid Course Prior to ILUVIEN\u00c2\u00ae Use for IOP Outcomes","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Alimera Sciences"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Paladin Phase 4 Study Confirms ILUVIEN\u00ae Patients' Reduced Need for Multiple Treatments","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Alimera Sciences"},{"orgOrder":0,"company":"AffaMed Therapeutics","sponsor":"Ocular Therapeutix","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AffaMed Therapeutics Announces Completion of Patient Enrollment in the Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA\u00ae in Cataract Surgery Patients","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"AffaMed Therapeutics"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CEQUA\u00ae (cyclosporine ophthalmic solution) 0.09% Phase 4 Data Showed Sustained Improvement in Dry Eye Disease Signs and Symptoms in Patients Switched From Restasis\u00ae (cyclosporine ophthalmic emulsion) 0.05%","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Peptide","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Sun Pharmaceutical Industries Limited"}]
Cequa (cyclosporine ophthalmic solution) is a patented, novel, proprietary nanomicellar NCELL formulation of cyclosporine in a clear, preservative-free, aqueous solution. It is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye).
Dextenza (dexamethasone), a corticosteroid intracanalicular insert, is FDA-approved for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis.
PALADIN phase 4 data demonstrate ILUVIEN (fluocinolone acetonide) patients experienced on average an increase in visual acuity, a significant decrease in retinal thickness and a predictable and manageable safety profile over 36 months.
Iluvien (fluocinolone acetonide intravitreal implant), is designed to release sub-microgram levels, a corticosteroid, for 36 months, to reduce recurrence of disease and number of treatments required, enabling patients to maintain vision longer with fewer injections.
ILUVIEN (fluocinolone acetonide), sustained release intravitreal implant, demonstrated statistically significant improvements in best-corrected visual acuity, central subfield thickness, also resulted in a 70.5% reduction in treatment burden at 36 months in PALADIN Study.
The real-world data from the Phase 4 PALADIN study show that patients receiving one or less total injections per year for their DME after the ILUVIEN injection increased three-fold from prior to the ILUVIEN injection.
The clinical trial is designed to demonstrate the clinical efficacy and safety of LO2A in DES patients with Sjögren's syndrome. Phase IV study aims at expanding LO2A's current approved status.
This agreement will advance Wize Pharma's ongoing clinical program for LO2A, currently in a Phase IV study for the treatment of dry eye syndrome in patients with Sjogren's.